Bertrand Coiffier, MD, PhD, on the Phase III LyMa Trial

2014 ASH Annual Meeting

Bertrand Coiffier, MD, PhD, of Centre Hospitalier Lyon-Sud, offers his thoughts on abstract 146, “Rituximab Maintenance vs Wait and Watch After Four Courses of R-DHAP Followed By Autologous Stem Cell Transplantation in Previously Untreated Young Patients With Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective LyMa Trial, a Lysa Study,” presented by Steven Le Gouill, MD, PhD.

Julie M. Vose, MD, MBA, FASCO, on Nivolumab in Relapsed/Refractory Hodgkin Lymphoma

Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, offers her thoughts on abstract 289, “Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma: Preliminary Safety, Efficacy, and Biomarker Results of a Phase I Study,” presented by Philippe Armand, MD, PhD.

Leukemia

James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD

James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD, on Progress Made Against AML and APL

James. O Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, and Richard M. Stone, MD, of the Dana-Farber Cancer Institute, discuss advances in treating acute myeloid leukemia and the acute promyelocytic leukema subtype.

Multiple Myeloma

Sagar Lonial, MD

Sagar Lonial, MD, on Monoclonal Antibodies in Multiple Myeloma

Sagar Lonial, MD, of Winship Cancer Institute, offers his thoughts on abstract 302, “Final Results for the 1703 Phase Ib/II Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma,” presented by Paul G. Richardson, MD; abstract 84, “Safety and Efficacy of Daratumumab With Lenalidomide and Dexamethasone in Relapsed or Relapsed/ Refractory Multiple Myeloma,” presented by Torben Plesner, MD; and “A Phase Ib Dose Escalation Trial of SAR650984 (Anti–CD-38 mAb) in Combination With Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma,” presented by Thomas G. Martin III, MD.

Leukemia

Richard M. Stone, MD

Richard M. Stone, MD, on the UK NCRI AML17 Trial

Richard M. Stone, MD, of Dana-Farber Cancer Institute, offers his thoughts on abstract 7, “A Randomized Comparison of Daunorubicin 90 mg/m² vs 60 mg/m² in AML Induction: Results From the UK NCRI AML17 Trial in 1206 Patients,” presented by Alan K. Burnett, MD.

Time: 1:29

Hematologic Malignancies

Keith McCrae, MD

Keith McCrae, MD, on Caplacizumab in Thrombotic Thrombocytopenic Purpura

Keith McCrae, MD, of the Cleveland Clinic, offers his thoughts on abstract 229, “Caplacizumab, Anti-Vwf Nanobody Potentially Changing the Treatment Paradigm in Thrombotic Thrombocytopenic Purpura: Results of the TITAN Trial,” presented by Flora Peyvandi, MD.

Jan

Today In Oncology

Bertrand Coiffier, MD, PhD, on the Phase III LyMa Trial

Related Videos

Julie M. Vose, MD, MBA, FASCO, on Nivolumab in Relapsed/Refractory Hodgkin Lymphoma

James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD, on Progress Made Against AML and APL

Sagar Lonial, MD, on Monoclonal Antibodies in Multiple Myeloma

Richard M. Stone, MD, on the UK NCRI AML17 Trial

Keith McCrae, MD, on Caplacizumab in Thrombotic Thrombocytopenic Purpura

Camrelizumab Plus Rivoceranib vs Sorafenib for the First-Line Treatment of Unresectable Hepatocellular Carcinoma

Curative Treatment After First-Line Immunotherapy Improves Survival in HCC

Perioperative Camrelizumab Plus Rivoceranib vs Surgery Alone in Hepatocellular Carcinoma

Which First-Line Systemic Therapy Balances Survival and Quality of Life in Advanced Hepatocellular Carcinoma?

Adding Dendritic Cell Vaccination to Hepatocellular Carcinoma Therapy